北京因科瑞斯

Beijing Increas Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule drugs for oncology. The company focuses on targeting the Wnt/beta-catenin signaling pathway, a critical driver of tumor progression and resistance in various cancers. Its lead candidate, IC-001, is a potent small molecule inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors, including colorectal cancer. Increas Biotech utilizes its proprietary drug discovery platform to identify novel therapeutic targets and develop precision medicines. The company is backed by prominent investors such as Northern Light Venture Capital and IDG Capital, aiming to address significant unmet needs in the field of oncology.